Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients

Standard

Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. / Wenzel, Mike; Würnschimmel, Christoph; Chierigo, Francesco; Tian, Zhe; Shariat, Shahrokh F; Terrone, Carlo; Saad, Fred; Tilki, Derya; Graefen, Markus; Roos, Frederik C; A Kluth, Luis; Mandel, Philipp; Chun, Felix K H; Karakiewicz, Pierre I.

in: PROSTATE, Jahrgang 81, Nr. 14, 10.2021, S. 1055-1063.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Wenzel, M, Würnschimmel, C, Chierigo, F, Tian, Z, Shariat, SF, Terrone, C, Saad, F, Tilki, D, Graefen, M, Roos, FC, A Kluth, L, Mandel, P, Chun, FKH & Karakiewicz, PI 2021, 'Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients', PROSTATE, Jg. 81, Nr. 14, S. 1055-1063. https://doi.org/10.1002/pros.24202

APA

Wenzel, M., Würnschimmel, C., Chierigo, F., Tian, Z., Shariat, S. F., Terrone, C., Saad, F., Tilki, D., Graefen, M., Roos, F. C., A Kluth, L., Mandel, P., Chun, F. K. H., & Karakiewicz, P. I. (2021). Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. PROSTATE, 81(14), 1055-1063. https://doi.org/10.1002/pros.24202

Vancouver

Bibtex

@article{e10c736ac00b4a8b86cd23565afd109e,
title = "Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients",
abstract = "BACKGROUND: Number of positive prostate biopsy cores represents a key determinant between high versus very high-risk prostate cancer (PCa). We performed a critical appraisal of the association between the number of positive prostate biopsy cores and CSM in high versus very high-risk PCa.METHODS: Within Surveillance, Epidemiology, and End Results database (2010-2016), 13,836 high versus 20,359 very high-risk PCa patients were identified. Discrimination according to 11 different positive prostate biopsy core cut-offs (≥2-≥12) were tested in Kaplan-Meier, cumulative incidence, and multivariable Cox and competing risks regression models.RESULTS: Among 11 tested positive prostate biopsy core cut-offs, more than or equal to 8 (high-risk vs. very high-risk: n = 18,986 vs. n = 15,209, median prostate-specific antigen [PSA]: 10.6 vs. 16.8 ng/ml, <.001) yielded optimal discrimination and was closely followed by the established more than or equal to 5 cut-off (high-risk vs. very high-risk: n = 13,836 vs. n = 20,359, median PSA: 16.5 vs. 11.1 ng/ml, p < .001). Stratification according to more than or equal to 8 positive prostate biopsy cores resulted in CSM rates of 4.1 versus 14.2% (delta: 10.1%, multivariable hazard ratio: 2.2, p < .001) and stratification according to more than or equal to 5 positive prostate biopsy cores with CSM rates of 3.7 versus 11.9% (delta: 8.2%, multivariable hazard ratio: 2.0, p < .001) in respectively high versus very high-risk PCa.CONCLUSIONS: The more than or equal to 8 positive prostate biopsy cores cutoff yielded optimal results. It was very closely followed by more than or equal to 5 positive prostate biopsy cores. In consequence, virtually the same endorsement may be made for either cutoff. However, more than or equal to 5 positive prostate biopsy cores cutoff, based on its existing wide implementation, might represent the optimal choice.",
author = "Mike Wenzel and Christoph W{\"u}rnschimmel and Francesco Chierigo and Zhe Tian and Shariat, {Shahrokh F} and Carlo Terrone and Fred Saad and Derya Tilki and Markus Graefen and Roos, {Frederik C} and {A Kluth}, Luis and Philipp Mandel and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2021 The Authors. The Prostate published by Wiley Periodicals LLC.",
year = "2021",
month = oct,
doi = "10.1002/pros.24202",
language = "English",
volume = "81",
pages = "1055--1063",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "14",

}

RIS

TY - JOUR

T1 - Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients

AU - Wenzel, Mike

AU - Würnschimmel, Christoph

AU - Chierigo, Francesco

AU - Tian, Zhe

AU - Shariat, Shahrokh F

AU - Terrone, Carlo

AU - Saad, Fred

AU - Tilki, Derya

AU - Graefen, Markus

AU - Roos, Frederik C

AU - A Kluth, Luis

AU - Mandel, Philipp

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

N1 - © 2021 The Authors. The Prostate published by Wiley Periodicals LLC.

PY - 2021/10

Y1 - 2021/10

N2 - BACKGROUND: Number of positive prostate biopsy cores represents a key determinant between high versus very high-risk prostate cancer (PCa). We performed a critical appraisal of the association between the number of positive prostate biopsy cores and CSM in high versus very high-risk PCa.METHODS: Within Surveillance, Epidemiology, and End Results database (2010-2016), 13,836 high versus 20,359 very high-risk PCa patients were identified. Discrimination according to 11 different positive prostate biopsy core cut-offs (≥2-≥12) were tested in Kaplan-Meier, cumulative incidence, and multivariable Cox and competing risks regression models.RESULTS: Among 11 tested positive prostate biopsy core cut-offs, more than or equal to 8 (high-risk vs. very high-risk: n = 18,986 vs. n = 15,209, median prostate-specific antigen [PSA]: 10.6 vs. 16.8 ng/ml, <.001) yielded optimal discrimination and was closely followed by the established more than or equal to 5 cut-off (high-risk vs. very high-risk: n = 13,836 vs. n = 20,359, median PSA: 16.5 vs. 11.1 ng/ml, p < .001). Stratification according to more than or equal to 8 positive prostate biopsy cores resulted in CSM rates of 4.1 versus 14.2% (delta: 10.1%, multivariable hazard ratio: 2.2, p < .001) and stratification according to more than or equal to 5 positive prostate biopsy cores with CSM rates of 3.7 versus 11.9% (delta: 8.2%, multivariable hazard ratio: 2.0, p < .001) in respectively high versus very high-risk PCa.CONCLUSIONS: The more than or equal to 8 positive prostate biopsy cores cutoff yielded optimal results. It was very closely followed by more than or equal to 5 positive prostate biopsy cores. In consequence, virtually the same endorsement may be made for either cutoff. However, more than or equal to 5 positive prostate biopsy cores cutoff, based on its existing wide implementation, might represent the optimal choice.

AB - BACKGROUND: Number of positive prostate biopsy cores represents a key determinant between high versus very high-risk prostate cancer (PCa). We performed a critical appraisal of the association between the number of positive prostate biopsy cores and CSM in high versus very high-risk PCa.METHODS: Within Surveillance, Epidemiology, and End Results database (2010-2016), 13,836 high versus 20,359 very high-risk PCa patients were identified. Discrimination according to 11 different positive prostate biopsy core cut-offs (≥2-≥12) were tested in Kaplan-Meier, cumulative incidence, and multivariable Cox and competing risks regression models.RESULTS: Among 11 tested positive prostate biopsy core cut-offs, more than or equal to 8 (high-risk vs. very high-risk: n = 18,986 vs. n = 15,209, median prostate-specific antigen [PSA]: 10.6 vs. 16.8 ng/ml, <.001) yielded optimal discrimination and was closely followed by the established more than or equal to 5 cut-off (high-risk vs. very high-risk: n = 13,836 vs. n = 20,359, median PSA: 16.5 vs. 11.1 ng/ml, p < .001). Stratification according to more than or equal to 8 positive prostate biopsy cores resulted in CSM rates of 4.1 versus 14.2% (delta: 10.1%, multivariable hazard ratio: 2.2, p < .001) and stratification according to more than or equal to 5 positive prostate biopsy cores with CSM rates of 3.7 versus 11.9% (delta: 8.2%, multivariable hazard ratio: 2.0, p < .001) in respectively high versus very high-risk PCa.CONCLUSIONS: The more than or equal to 8 positive prostate biopsy cores cutoff yielded optimal results. It was very closely followed by more than or equal to 5 positive prostate biopsy cores. In consequence, virtually the same endorsement may be made for either cutoff. However, more than or equal to 5 positive prostate biopsy cores cutoff, based on its existing wide implementation, might represent the optimal choice.

U2 - 10.1002/pros.24202

DO - 10.1002/pros.24202

M3 - SCORING: Journal article

C2 - 34312910

VL - 81

SP - 1055

EP - 1063

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 14

ER -